343 POSTER Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor
H.A. Burris, G. Hudes, S. Jones, J. Cheng, D. Spigel, M. Mariani, H. Macdonald, M. Rocchetti, B. Laffranchi, R.B. CohenVolume:
4
Year:
2006
Language:
english
DOI:
10.1016/s1359-6349(06)70348-2
File:
PDF, 57 KB
english, 2006